By Ben Fidler | September 25, 2026
The biopharmaceutical sector continues to move at a breakneck pace, marked by a blend of high-stakes litigation, transformative licensing agreements, and a steady stream of regulatory milestones. As of late September 2026, the industry is grappling with the implications of a significant legal verdict involving Nektar Therapeutics and Eli Lilly, while simultaneously witnessing a shift toward long-acting chronic care solutions led by Novo Nordisk. Below is a comprehensive analysis of the most critical developments from the past 48 hours.
1. Novo Nordisk’s Strategic Expansion into Long-Acting Therapeutics
In a move designed to secure its dominance in the cardiometabolic space, Novo Nordisk has entered into a landmark global license and collaboration agreement with the Swedish biotech firm Nanexa. The deal, which could see Novo paying up to 1.165 billion euros ($1.32 billion), centers on the utilization of Nanexa’s proprietary "PharmaShell" drug delivery technology.
The Technology and Its Potential
PharmaShell is a sophisticated coating technology that allows for the controlled release of active pharmaceutical ingredients. By applying this shell to existing molecules, developers can effectively extend the duration of a drug’s efficacy within the human body. Novo Nordisk intends to leverage this platform across five distinct development programs, focusing on obesity, Type 2 diabetes, and related cardiometabolic conditions.
The core objective of this partnership is to move away from the daily injection model that has defined diabetes care for decades. Instead, Novo and Nanexa are targeting formulations that require administration only once a month or, potentially, once per quarter. For patients, this represents a massive improvement in treatment burden and adherence; for Novo, it represents a "moat" around their core portfolio that competitors will find difficult to breach.
This is not Nanexa’s first foray into high-level partnerships; the company established a similar pact with Moderna just last year, suggesting that their drug delivery platform is becoming an industry standard for companies looking to extend the lifecycle of their injectable therapeutics.
2. Chronology of Recent Sector Developments
The following timeline summarizes the key events that have defined the current industry discourse:
- August 2023: Nektar Therapeutics initiates a lawsuit against Eli Lilly, alleging that the latter intentionally undermined their collaborative autoimmune project following Lilly’s acquisition of a competing treatment.
- March 2026: The FDA grants approval for Novo Nordisk’s Awiqli, the first once-weekly basal insulin for adults with Type 2 diabetes.
- July 2026: The FDA approves Welireg for use in the adjuvant setting following surgical intervention for renal cell carcinoma.
- September 24, 2026: A California federal jury delivers a verdict in the Nektar v. Lilly case, awarding Nektar $90 million in damages.
- September 25, 2026: The FDA officially approves Eli Lilly’s Onswik (once-weekly insulin), intensifying the rivalry with Novo Nordisk’s Awiqli.
- September 25, 2026: Novo Nordisk announces the multi-billion dollar Nanexa licensing deal.
3. Legal Wrangling: The Nektar-Lilly Verdict
The outcome of the litigation between Nektar Therapeutics and Eli Lilly serves as a cautionary tale regarding the complexities of pharmaceutical partnerships. The dispute centered on a collaborative effort to develop an autoimmune drug. Nektar alleged that Lilly, after acquiring a rival treatment (Dermira), actively sabotaged the development of their joint project to prioritize its own internal assets.
While the jury found in favor of Nektar on the merits of their complaint, the financial outcome was a significant disappointment for the plaintiff. Nektar had sought nearly $1 billion in damages, arguing that Lilly’s actions had effectively destroyed the value of the collaboration. The $90 million award, while a legal victory, represents a fraction of the requested sum.
According to regulatory filings, the verdict is still subject to post-trial proceedings. Market analysts suggest that while Nektar has been vindicated, the low award amount may impact their future valuation and ability to fund independent research pipelines.
4. Regulatory Landscape: The Insulin Arms Race and Merck’s Expansion
The FDA’s regulatory calendar has been particularly active this week, with major approvals impacting the diabetes and oncology markets.
The Weekly Insulin Battle
The approval of Eli Lilly’s Onswik marks a pivotal shift in the management of Type 2 diabetes. Clinical data demonstrated that Onswik is non-inferior to daily insulin shots, providing a significant quality-of-life benefit for patients. This approval sets the stage for a head-to-head market battle with Novo Nordisk’s Awiqli. Given that both products aim to solve the same problem—reducing the frequency of injections—the competition will likely shift toward pricing, insurance coverage, and patient support programs.
Merck’s Sustained Momentum with Welireg
Merck & Co. continues to extract value from its 2019 acquisition of Peloton Therapeutics. The FDA’s latest clearance for Welireg (belzutifan) allows for its use in patients whose kidney cancer has progressed following treatment with Keytruda. With $470 million in sales recorded in the first half of 2026 alone, Welireg is proving to be a cornerstone of Merck’s non-oncology portfolio, reinforcing the value of strategic bolt-on acquisitions.
5. Clinical Uncertainty: Acadia’s Alzheimer’s Gamble
Perhaps the most precarious situation currently unfolding involves Acadia Pharmaceuticals and their drug remlifanserin. The company recently announced that the drug "narrowly missed" statistical significance in a Phase 2 trial intended to treat hallucinations and delusions in patients with Alzheimer’s disease psychosis.
Despite this setback, Acadia has chosen to proceed with two ongoing Phase 3 trials. The industry is currently divided on this decision. Stifel analyst Paul Matteis has noted that while there remains a chance for success, the efficacy data observed in the mid-stage trial was "quite modest." The "favorable safety profile" cited by Acadia is likely the primary factor keeping the project alive, as the market for Alzheimer’s-related psychiatric treatments remains largely underserved and highly lucrative. Investors reacted sharply to the news, sending shares down by double digits, signaling a lack of confidence in the gamble.
6. Implications for the Future
The events of the past week highlight three dominant trends within the biopharma industry:
- The "Long-Acting" Revolution: Companies are no longer satisfied with simply providing effective drugs; they are now competing to provide the most convenient ones. The Novo-Nanexa deal is a clear indicator that the industry is pivoting toward "administration-frequency" as a primary competitive differentiator.
- Increased Scrutiny of Corporate Partnerships: The Nektar-Lilly case demonstrates that courts are increasingly willing to hold large pharma companies accountable for how they manage collaborative assets. This may lead to more rigid, restrictive, or transparent contracts in future industry alliances.
- The Resilience of the "Bolt-on" Acquisition Model: The success of Merck’s Welireg serves as a validation for the current M&A climate. By acquiring innovative, specialized assets and guiding them through the regulatory gauntlet, companies can generate significant revenue growth without relying solely on internal R&D.
As we look toward the final quarter of 2026, the focus will undoubtedly shift to how these newly approved drugs perform in the real world and whether the "narrow misses" in clinical trials—like that of Acadia—can be overcome by more robust Phase 3 designs. The sector remains a high-risk, high-reward environment where legal, clinical, and regulatory factors are inextricably linked.
Conclusion
The biopharma industry is in a state of constant evolution. Whether it is the technological advancement of drug delivery via Nanexa, the courtroom battles defining corporate ethics, or the rigorous FDA approval process for new diabetes and oncology treatments, these developments set the tone for the healthcare sector in the coming year. Stakeholders must remain vigilant as these clinical and legal narratives continue to unfold.
About the Author
